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A b s t r a c t  
We have synthesized a sustained-release lidocaine sheet (SRLS) and injectable sustained-release 
lidocaine particles (SRLP) using biodegradable polymers. In the present study, we performed an 
exploratory first clinical trial of the SRLS in healthy volunteers as a prelude to patient administration. 
This trial is meant as an initial intervention in ultimately developing and refining the SRLP. 
We evaluated the intensity and duration of analgesia of the SRLS compared with 8% lidocaine 
spray. In Protocol 1, we applied the SRLS piece to the mucous membrane of the nasal vestibule. 
We examined the local pain threshold over 72 h after administration, and removed the SRLS after 
72 h. Individuals that finished Protocol 1 underwent Protocol 2, in which we applied 8% lidocaine 
spray. 
Twelve volunteers were enrolled and seven of these volunteers finished Protocol 1. All seven 
individuals who completed Protocol 1 also completed Protocol 2. The mean pain thresholds were 32 
g, 78 g, 90 g, 90 g, 87 g, and 87 g at pre-administration and 4 h, 10 h, 24 h, 48 h, and 72 h after 
administration, respectively, in Protocol 1, and 36 g, 85 g, 49 g, and 33 g at pre-administration and 
15 min, 2 h, and 4 h, respectively, in Protocol 2. 
A sustained-release lidocaine using biodegradable polymers was applied as a sheet in humans for 
the first time in the world. It maintained significant analgesia for 72 h without major toxicities. 
Furthermore, degree of analgesia provided by the SRLS throughout the entire study was similar to 
that provided by the 8% lidocaine spray. It may suitable for management of postoperative pain 
especially in outpatients. 
Keywords: sustained-release lidocaine, 8% lidocaine spray, biodegradable polymer, healthy 
volunteer, clinical trial, postoperative analgesia 
 
Introduction 
Appropriate postsurgical pain management contributes to improved 
healing, faster patient mobilization, shortened hospital stays, 
reduced healthcare costs, and increased patient satisfaction [1-4]. 
Additionally, aggressive management of acute postoperative pain 
by pre-emptive and multimodal analgesia may reduce the 
incidence of chronic postoperative pain [5-6]. 
Sustained-release local anesthetics may provide long-acting 
postoperative analgesia through a single administration at a 
surgical wound, around a nerve innervating the operation site or 
into epidural space without a continuous infusion catheter. Such a 
strategy could become an important addition to current multimodal 
approaches to postsurgical pain management by reducing the 
consumption of supplemental analgesics including opioids-related 
or continuous infusion catheter-related complications such as 
infection, bleeding, and compartment syndrome. Sustained-release 
versions of various local anesthetics have been produced in 
various forms [7-9] in particular, prolonged analgesic effects in 
animals [10-17] and humans [18-20] have been reported for 
sustained-release bupivacaine. Lidocaine is widely used as a local 
anesthetic because it has a wide safety margin for cardiac toxicity. 
Several sustained-release lidocaine formulations have already 
been produced [21-22] and the anesthetic effects of sciatic nerve 
block [23-25], epidural block [26,27], or local analgesia[28] by 
sustained-release lidocaine have been examined in healthy 
animals.  
We have synthesized a sustained-release lidocaine sheet 
(SRLS)using biodegradable polymers, and we previously 
demonstrated the safety and efficacy of the SRLS for sciatic nerve 
block in a rat model of postoperative pain [29]. Furthermore, we 
have also synthesized injectable sustained-release lidocaine 
particles (SRLP), that are not sheets, from the same biodegradable 
polymers used for the SRLS, and we demonstrated that epidural 
injection of these particles produced prolonged anti-hypersensitivity 
in a rat model of postoperative pain with no major complications 
[17]. In the present study, we performed an exploratory first clinical 
trial for the SRLS in healthy volunteers prior to administration of the 
SRLS to patients. This trial is meant as an initial intervention in 
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ultimately developing and refining the SRLP for administration into 
epidural space or around sensory nerves. 
Materials and methods 
This study was approved by the institutional review board of 
Gunma University Hospital and registered with the University 
Hospital Medical Information Network (UMIN000008248, 
UMIN000009915). Written informed consent was obtained from all 
volunteers before enrollment. The aim of this clinical trial was to 
evaluate the duration and intensity of analgesia and the safety of 
the SRLS in the normal mucous membrane of healthy volunteers. 
Subjects 
The volunteers in this study were selected from the public and 
were compensated for damages with accident insurance. All 
volunteers were paid for their participation. All volunteers had 
medical records at Gunma University Hospital and were screened 
within 30 days prior to the start of administration. Healthy males 
aged 20 to 40 years were eligible to participate in this study. 
Subjects were excluded from participation if they had any diseases 
of the nasal cavities, allergies to amide-type local anesthetics, 
arrhythmia, or difficulty communicating, or if they had consumed 
any medications within 1 week of the start of the study. Individuals 
who were considered to be inappropriate for this study by a 
physician for any other reason were also excluded. The volunteers 
interviewed regarding their medical history and underwent a blood 
examination to determine the hemoglobin concentration and blood 
cell counts for white blood cells and platelets. The blood samples 
were also subjected to biochemical examination for total protein 
(TP), aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), blood urea nitrogen (BUN), creatinine, Na, K, and Cl levels. 
The volunteers also underwent resting 12-lead electrocardiography 
(ECG).  
Preparation of the study drug 
We prepared SRLS loaded with 40% (w/w) lidocaine for this clinical 
study. We dissolved lidocaine (804.1mg; lidocaine powder; Sigma-
Aldrich Corporation, St. Louis, MO) and PLGA (1,204mg; 50:50 
poly (DL-lactide-co-glycolide) ester-terminated polymer;inherent 
viscosity, 0.55-0.75;Durect Corporation, Cupertino, CA,USA) in 
chloroform (6.310ml; º99.5%;containing 100-200ppm amylenes as 
a stabilizer; 1.492g/mL at 25ĈC; Sigma-Aldrich Corporation, St. 
Louis, MO,USA), and then poured the lidocaine/PLGA/chloroform 
solution into Petri dishes (inner diameter 48mm, area 
approximately 7616mm2). The solutions were then desiccated for 2 
days at 25ĈC in a class II, type A2 biological safety cabinet (Thermo 
Fisher Scientific Inc., Waltham, MA, USA) whose interior had been 
sterilized with a germicidal light, followed by1 week at 37ĈC in a 
vacuum-drying oven (Advantec Toyo Kaisha, Ltd Bunkyo, Tokyo, 
Japan)to allow the chloroform to completely evaporate. The drying 
converted the solutions to sheets, which were removed from the 
dishes and cut into pieces of approximately1cmï1cm, each 
weighing approximately 50mg and containing approximately 20 mg 
of lidocaine. The prepared SRLS samples were then frozen and 
stored until use. 
We determined the capacity of the SRLS to release lidocaine in 
vitro before the study. SRLS samples were placed into a vessel 
filled with 50mL of phosphate buffer (pH 7.40) prepared from 
monobasic sodium phosphate (12.69g) and dibasic sodium 
phosphate (43.74g) in 4L of distilled water. We prepared four 
vessels in the same way and sampled 0.5ml of the buffer from 
each of the vessels at several time points. The vessels were 
placed in a 37ĈC incubator except when sampled. The lidocaine 
concentration in each sample was measured by SRL Inc. 
(Shinjuku, Tokyo, Japan) using an enzyme immunoassay (EIA).  
Evaluation of pain thresholds 
The pain threshold was measured using anelectronic Von Frey 
anesthesiometer (IITC Life Science Inc., Woodland Hills, CA, 
USA). The polypropylene tip of the anesthesiometer was applied 
perpendicularly to the test site with a gradual increase in pressure 
by the subject, which released it from the site by himself in eliciting 
pain. The force needed to elicit pain was automatically recorded as 
a threshold in grams by the pressure transducer of the 
anesthesiometer. 
Study Protocol 1 
After measuring the pre-administration pain threshold, we applied a 
50 mg SRLS piece (estimated to contain 20 mg of lidocaine) to one 
side of thenasal vestibule, and then fixed it in place using a ball of 
cotton wool (Figure 1).When the SRLS was applied, it was applied 
dry because it was expected to be wetted by the nasal mucus. To 
prevent the lidocaine from being released through the ball of cotton 
wool into the nasal cavity, one side of the sheet (the side not 
exposed to the nasal mucosa) was coated with a transparent thin 
polyurethane film using an acrylic adhesive (Tegaderm ™, 
Sumitomo 3M Limited, Shinagawa, Tokyo, Japan). The SRLS and 
the cotton wool were temporarily removed in every examination of 
the local pain threshold, and then the SRLS was placed back in its 
original position with a new cotton ball. We examined the local pain 
threshold and observed the administered site at 4 h, 10 h, 24 h, 48 
h, and 72h after administration. The SRLS was removed after 72 h. 
We also performed medical interviews or examinations as needed 
during the application. All subjects underwent observation of the 
administered site, a medical interview or examination, and a blood 
examinations at one week after administration to detect serious 
side effects such as liver injury, renal injury, or pancytopenia. 
Bathing or exercise that could wet the ball of cotton wool in the 
nasal cavity was prohibited during the study (Table 1). 
The sustained-release lidocaine sheet (SRLS) was applied to one 
side of the nasal vestibule (Protocol 1). The figures show a front 
view (left) and a side view (right) illustrating the right nasal cavity. 
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Figure 1: The position of the SRLS applied 
 
 
Table 1: Timetable of Protocol 1 
 Pre- 4 h 10 h 24 h 48 h 72 h 1 w 
Pain threshold o o o o o o  
Observation of local site o o o o o Ĥo 
Medical interview/examination When needed Ĥo 
Blood examination  Ĥo 
 
Study Protocol 2 
Individuals that finished Protocol 1underwentProtocol 2 after at 
least one month had passed. In Protocol 2, after measuring the 
pre-administration pain threshold, we applied three pumps 
(estimated to contain 24 mg of lidocaine) of a 8% lidocaine spray 
(Xylocaine® pump spray 8%, AstraZeneca K.K., Osaka, Japan), a 
local anesthetic in current clinical use, to the same side of the 
nasal vestibule that had previously received the SRLS. We 
examined the local pain threshold at 15min, 2 h, and 4h after 
administration as described above. We performed medical 
interviews and examinations as needed but did not perform the 
blood examination after administration of the lidocaine spray. 
Because the duration of the effect of the lidocaine spray was 
expected to be short, we measured the pain thresholds at shorter 
time points than in Protocol 1 (Table 2). 
 
Table 2. Timetable of Protocol 2 
 Pre- 15 min 2 h 4 h
Pain threshold Ĥo oĤ o o
Observation of local site   Ĥo Ĥo o
Medical interview/examination When needed
Blood examinations    
Statistical Analysis 
The population in which safety was confirmed included all subjects 
who received the SRLS. The population used for the efficacy 
analyses thus included all subjects who received the SRLS and 
who underwent at least one pain threshold measurement after 
administration. 
The pain threshold at each time point was compared with the pre-
administration value using a two-sided paired t-test. The value for 
each blood examination parameter at one week was also 
compared with the pre-administration value using a two-sided 
paired t-test. 
All statistical analyses were performed using EZR (Saitama 
Medical Center, Jichi Medical University), which is a graphical user 
interface for R (The R Foundation for Statistical Computing, version 
2.13.0). EZR is a modified version of R Commander (version 1.6-3) 
that adds statistical functions frequently used in biostatistics [30]. 
Results 
The disposition of the volunteers is presented in Figure 2. Thirteen 
volunteers were screened, and 12 were enrolled. Seven of these 
volunteers finished Protocol 1; the other five volunteers 
discontinued the protocol 1(see Safety Assessment). All seven 
individuals who completed Protocol 1also completed Protocol 2. 
The mean age was 28 years (range, 23-34 years), and the mean 
weight was 62kg (range, 51-80kg). The mean (μstandard deviation: 
SD) weight of the SRLS actually administered was 55.7 (μ4.7) mg, 
the mean dose of applied lidocaine that was estimated to be in the 
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nose that may have been caused by the use of a ball of cotton 
wool that was too large. 
While two subjects finished Protocol 1, one experienced 
hypoesthesia in the tongue in the morning because post-nasal drip 
carried the lidocaine from the nose to the throat when the subject 
was sleeping at night. One subject also present a slight increase in 
liver enzyme activity (AST 40 IU/L, ALT 46 IU/L) and K levels (5.1 
mEq/L) after administration, although this increase may have been 
caused by hemolysis when the blood was drawn. These 
parameters had returned to normal levels (AST 27IU/L, ALT 
40IU/L, and K 4.4mEq/L) at the blood examination one week later. 
Overall, no clinically obvious meaningful shifts were noted in any of 
the chemistry or hematology values from screening. Almost all of 
the subjects experienced reactive serous rhinorrhea. 
Discussion 
In the present study, we demonstrated efficacy and safety of the 
sustained-release lidocaine sheet (SRLS) for providing analgesia 
to the normal mucous membrane of human volunteers. The SRLS 
significantly increased the mean pain threshold relative to the pre-
administration for the entire 72 h duration of the study, but the 8% 
lidocaine spray was only effective for 15 min after administration. 
Furthermore, the extent of analgesia throughout the study in the 
SRLS-treated group was similar to that observed at 15 min inthe 
8% lidocaine spray. Therefore, the efficacy of the SRLS was as 
high as that of the 8% lidocaine spray (the highest concentration in 
current clinical use) and maintained for 72 h. We did not examine 
the effect of the SRLS after 72 h because of the burden to the 
volunteers. However, we consider that the analgesic effect of the 
SRLS would likely last longer than 72 h because we previous 
observed an SRLS-mediated analgesic effect for 7 days after 
sciatic nerve block in a rat model of postoperative pain.29 The in 
vitro data also supported this statement, as 25.2 % of lidocaine 
was still remaining in the SRLS after 72 h. 
Although several complications occurred in this study, we 
considered that all of these complications were not related to 
SRLS; rather, they resulted from the study design, procedural 
complications or accidental complications in the study. Almost all of 
the subjects experienced reactive serous, which is not adverse but 
normal reaction in the nasal cavities. No subject reported 
symptoms of local anesthetic toxicity, although we did not measure 
the blood concentration of lidocaine in this study to reduce the 
burden on the volunteers. The mean dose of applied lidocaine that 
was estimated to be in the SRLS was 20.0 mg, which represents a 
common local anesthetic dose or dose for intravenous injection. 
Furthermore, the amount of lidocaine actually absorbed was less 
than 20.0 mg because the in vitro data showed that 25.2% of 
lidocaine was still remaining in the SRLS after 72 h. 
The SRLS and 8% lidocaine spray treatment effectively increased 
the mean pain threshold but did not produce complete local 
anesthesia, which suggests that the lidocaine did not reach the 
submucous tissue from mucous membrane. Although SRLS was 
equally effective to the 8% lidocaine spray in current clinical use, 
surface anesthesia is not our final aim for the clinical use of SRLS. 
Rather, our goal is to provide simple and effective postoperative 
analgesia with few side effects after a single administration of the 
sustained-release lidocaine particles (SRLP) around sensory 
nerves or into the epidural space, and to this end, we intentionally 
synthesized injectable SRLP from the same biodegradable 
polymers used for the SRLS so that it would be completely 
disintegrated and metabolized after administration. However, prior 
to clinical application of the SRLP, it was necessary to demonstrate 
the safety and efficacy of the SRLS, because we cannot easily 
remove the SRLP injected around sensory nerves or into the 
epidural space in an emergency. We chose to apply the SRLS to 
mucous membranes because they are easily accessible and allow 
easy removal of the SRLS in an emergency of the study. In 
particular, we chose the nasal mucous membrane because it is the 
most easily accessible among various mucous membranes. 
A sustained-release lidocaine using biodegradable polymers was 
applied as a sheet in humans for the first time in the world. We 
designed this study for the main purpose of demonstrating no 
major toxicity, the sample was therefore limited to the minimum 
size and male for an exploratory first clinical trial in humans, which 
was not randomized, controlled, and blinded trial. A large-size full 
placebo-controlled study or dose-response study is necessary as 
the next step in the clinical introduction of the SRLS to demonstrate 
true safety and efficacy, for example, for skin pain form heat burns 
or shingles. 
Epidural analgesia via an indwelling catheter is widely used for 
postoperative pain management. However, patients are 
increasingly treated perioperatively with anticoagulants or 
antiplatelets. Therefore, the invasive analgesic approach is now 
often replaced by continuous administration of opioids as in 
intravenous patient-controlled analgesia (IV-PCA) for management 
of postoperative pain to prevent neuroparalysis arising from the 
bleeding. However, the systemic administration of opioid 
analgesics is not always favorable because of side effects such as 
nausea, vomiting, sedation, respiratory depression, pruritus, 
constipation, and urinary retention. On the other hand, ultrasound 
guided peripheral nerve blocks are recently preferred for 
postoperative pain management because it is a relatively safety 
method for patients treated perioperatively with anticoagulants or 
antiplatelets. For getting long acting, these methods need 
continuous administration of local anesthetics using an indwelling 
catheter. Decreasing the risk of opioids-related adverse events 
without a continuous infusion catheter is particularly desirable in 
the outpatient setting; therefore, new postoperative analgesic 
methods are necessary. Not only outpatients but also inpatients 
may be promised long acting analgesia for postoperative pain 
without adverse events by wound local anesthesia, peripheral 
nerve block or epidural analgesia through a single injection of slow-
release local anesthetics. 
Conclusions 
We demonstrated that an SRLS applied to the normal mucous 
membrane in the nasal cavity produced analgesia for at least 72 h 
without major toxicities. The intensity of the effect was comparable 
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with that of 8% spray lidocaine treatment. Postsurgical pain is most 
intense within the first few days after surgery; therefore, a 
sustained-release lidocaine using biodegradable polymers 
including the SRLS maybe suitable for management of 
postoperative pain. 
Authors' Contributions 
TS carried out the studies, performed the statistical analysis, and 
drafted the manuscript. MT participated in the design and 
coordination of the study and helped to analyze the data and draft 
the manuscript. HO participated in the design and helped to draft 
the manuscript.YT helped to prepare the study drug.SS conceived 
of the study, participated in its design, and helped to draft the 
manuscript. All authors have seen the original study data, reviewed 
the analysis of the data, and approved the final manuscript. 
Acknowledgments 
This work was supported by a Grant-in-Aid for Research Activity 
Start-up from the Japan Society for the Promotion of Science, 




[1]. Crews JC. Epidural opioid analgesia. 
Crit Care Clin. 1990;6 (2):315-42. 
[2]. Carli F, Mayo N, Klubien K, Schricker 
T, Trudel J, Belliveau P. Epidural 
analgesia enhances functional 
exercise capacity and health-related 
quality of life after colonic 
surgery:results of a randomized trial. 
Anesthesiology 2002;97 (3): 540-49.  
[3]. Liu S, Carpenter RL, Neal JM. 
Epidural anesthesia and analgesia. 
Their role in postoperative outcome. 
Anesthesiology 1995;82(6):1474-506.  
[4]. Liu SS, Wu CL. Effect of 
postoperative analgesia on major 
postoperative complications: a 
systematic update of the evidence. 
Anesth Analg 2007; 104 (3): 689-702  
[5]. Macrae WA. Chronic post-surgical 
pain: 10 years on. Br J Anaesth. 2008; 
101 (1): 77-86. 
[6]. Kehlet H, Jensen TS, Woolf CJ. 
Persistent postsurgical pain: risk 
factors and prevention. Lancet 2006; 
367 (9522): 1618-25.  
[7]. Ratajczak-Enselme M, Estebe JP, 
Dollo G, Chevanne F, Bec D, 
Malinovsky JM, Ecoffey C, Le Corre 
P. Epidural, intrathecal and plasma 
pharmacokinetic study of epidural 
ropivacaine in PLGA-microspheres in 
sheep model. Eur J Pharm Biopharm 
2009; 72 (1): 54-61.  
[8]. Yin QQ, Wu L, Gou ML, Qian ZY, 
Zhang WS, Liu J. Long-lasting 
infiltration anaesthesia by lidocaine-
loaded biodegradable nanoparticles in 
hydrogel in rats. Acta Anaesthesiol 
Scand 2009; 53 (9): 1207-13.  
[9]. Chen PC, Park YJ, Chang LC, 
Kohane DS, Bartlett RH, Langer R, 
Yang VC. Injectable microparticle-gel 
system for prolonged and localized 
lidocaine release. I. In vitro 
characterization. J Biomed Mater Res 
A 2004; 70 (3): 412-9.  
[10]. Sokolsky-Papkov M, Golovanevski L, 
Domb AJ, Weiniger CF. Poly(DL:lactic 
acid-castor oil) 3:7-bupivacaine 
formulation: reducing burst effect 
prolongs efficacy in vivo. J Pharm Sci 
2010; 99 (6): 2732-8.  
[11]. Garry MG, Jackson DL, Geier HE, 
Southam M, Hargreaves KM. 
Evaluation of the efficacy of a 
bioerodible bupivacaine polymer 
system on antinociception and 
inflammatory mediator release. Pain 
1999; 82 (1): 49-55.  
[12]. Malinovsky JM, Le Corre P, Meunier 
JF, Chevanne F, Pinaud M, Leverge 
R, Legros F. A doseăresponse study 
of epidural liposomal bupivacaine in 
rabbits. J Control Release. 1999; 60 
(1): 111-9.  
[13]. Boogaerts JG, Lafont ND, Declercq 
AG, Luo HC, Gravet ET, Bianchi JA, 
Legros FJ. Epidural administration of 
liposome-associated bupivacaine for 
the management of postsurgical pain: 
a first study. J Clin Anesth 1994; 6 (4): 
315-20.  
[14]. Ohri R, Wang JC, Blaskovich PD, 
Pham LN, Costa DS, Nichols GA, 
Hildebrand WP, Scarborough NL, 
Herman CJ, Strichartz GR. Inhibition 
by local bupivacaine-releasing 
microspheres of acute postoperative 
pain from hairy skin incision. Anesth 
Analg. 2013; 117(3): 717-30 
[15]. Grant GJ, Lax J, Susser L, Zakowski 
M, Weissman TE, Turndorf H. Wound 
infiltration with liposomal bupivacaine 
prolongs analgesia in rats. Acta 
Anaesthesiol Scand 1997; 41 (2): 
204-7 
[16]. Dräger C, Benziger D, Gao F, Berde 
CB. Prolonged intercostal nerve 
blockade in sheep using controlled-
release of bupivacaine and 
dexamethasone from polymer 
microspheres. Anesthesiology 1998; 
89 (4): 969-79.  
[17]. Suto T, Obata H, Tobe M, Oku H, 
Yokoo H, Nakazato Y, Saito S. Long-
term effect of epidural injection with 
sustained-release lidocaine particles 
in a rat model of postoperative pain. 
Br J Anaesth. 2012 Dec; 109 (6): 957-
67.  
[18]. Bramlett K, Onel E, Viscusi ER, Jones 
K. A randomized, double-blind, dose-
ranging study comparing wound 
infiltration of DepoFoam bupivacaine, 
an extended-release liposomal 
bupivacaine, to bupivacaine HCl for 
postsurgical analgesia in total knee 
arthroplasty. Knee. 2012;19(5):530-6.  
Suzuki et al. International Journal of Drug Delivery 6 (1) 75-81 [2014] 
 
PAGE | 81 |
 
 
[19]. Smoot JD, Bergese SD, Onel E, 
Williams HT, Hedden W. The efficacy 
and safety of DepoFoam bupivacaine 
in patients undergoing bilateral, 
cosmetic, submuscular augmentation 
mammaplasty: a randomized, double-
blind, active-control study. Aesthet 
Surg J. 2012;32(1):69-76.  
[20]. Golf M, Daniels SE, Onel E. A phase 
3, randomized, placebo-controlled trial 
of DepoFoam® bupivacaine 
(extended-release bupivacaine local 
analgesic) in bunionectomy. Adv Ther. 
2011;28(9):776-88.  
[21]. Go¨rner T, Gref R, Michenot D, 
Sommer F, Tran MN, Dellacherie E. 
Lidocaine-loaded biodegradable 
nanospheres. I. Optimization of the 
drug incorporation into the polymer 
matrix. J Control Release 1999; 57 
(3): 259-68.  
[22]. Ricci EJ, Lunardi LO, Nanclares DM, 
Marchetti JM. Sustained release of 
lidocaine from Poloxamer 407 gels. Int 
J Pharm 2005; 288 (2): 235-44.  
[23]. Wang CF, Djalali AG, Gandhi A, 
Knaack D, De Girolami U, Strichartz 
G, Gerner P. An absorbable local 
anesthetic matrix provides several 
days of functional sciatic nerve 
blockade. Anesth Analg 2009; 108 (3): 
1027-33 
[24]. Paavola A, Yliruusi J, Kajimoto Y, 
Kalso E, Wahlstro¨m T, Rosenberg P. 
Controlled release of lidocaine from 
injectable gels and efficacy in rat 
sciatic nerve block. Pharm Res 1995; 
12 (12): 1997-2002 
[25]. Chen PC, Kohane DS, Park YJ, 
Bartlett RH, Langer R, Yang VC. 
Injectable microparticle-gel system for 
prolonged and localized lidocaine 
release. II. In vivo anesthetic effects. J 
Biomed Mater Res A 2004; 70 (3): 
459-66.  
[26]. Sato S, Baba Y, Tajima K, et al. 
Prolongation of epidural anesthesia in 
the rabbit with the use of a 
biodegradable copolymer paste 
containing lidocaine. Anesth Analg 
1995; 80 (1): 97-101.  
[27]. Mashimo T, Uchida I, Pak M, Shibata 
A, Nishimura S, Inagaki Y, Yoshiya I. 
Prolongation of canine epidural 
anesthesia by liposome encapsulation 
of lidocaine. Anesth Analg 1992; 74 
(6): 827-34.  
[28]. Yin QQ, Wu L, Gou ML, Qian ZY, 
Zhang WS, Liu J. Long-lasting 
infiltration anaesthesia by lidocaine-
loaded biodegradable nanoparticles in 
hydrogel in rats. Acta Anaesthesiol 
Scand 2009; 53 (9): 1207-13.  
[29]. Tobe M, Obata H, Suto T, Yokoo H, 
Nakazato Y, Tabata Y, Saito S. Long-
term effect of sciatic nerve block with 
slow-release lidocaine in a rat model 
of postoperative pain. Anesthesiology 
2010; 112 (6): 1473-81.  
[30]. Kanda Y. Investigation of the freely 
available easy-to-use software 'EZR' 
for medical statistics. Bone Marrow 
Transplant. 2013; 48 (3): 452-8.   
 
 
 
